Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
07:14am, Friday, 03'rd Jun 2022
Shares of Turning Point Therapeutics Inc. TPTX, +2.21% more than doubled, up 116.7%, in premarket trading Friday, after the clinical-stage oncology company agreed to be acquired by biopharmaceutical c
Bristol Myers to buy Turning Point for $4.1 billion
07:07am, Friday, 03'rd Jun 2022
Bristol Myers Squibb said on Friday it would acquire Turning Point Therapeutics Inc for $4.1 billion in cash to gain access to its experimental cancer drug.
Three-Stock Lunch: Kinder Morgan, M&T Bank and Bristol-Myers Squibb
03:38pm, Thursday, 02'nd Jun 2022
Steve Grasso, Grasso Global CEO and CNBC contributor, joins 'Power Lunch' to discuss Grasso's thoughts on stocks like Kinder Morgan, M&T Bank and Bristol-Myers Squibb.
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein 38th Annual Strategic Decisions Conference (Transcript)
02:09pm, Thursday, 02'nd Jun 2022
Bristol-Myers Squibb Company (NYSE:BMY ) Bernstein 38th Annual Strategic Decisions Conference Call June 2, 2022 8:00 AM ET Company Participants Giovanni Caforio - Chief Executive Officer Samit Hirawat
Bristol Myers Squibb, Immatics expand CAR-T agreement
07:44am, Thursday, 02'nd Jun 2022
Shares of Immatics IMTX, +3.85% gained 9.0% in premarket trading on Thursday after the company said its deal with Bristol Myers Squibb Inc. BMY, -0.65% has expanded to include several off-the-shelf TC
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
04:33pm, Monday, 30'th May 2022
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
Bristol Myers Squibb: A Safe Spot For A Worrisome Investor
03:35am, Saturday, 28'th May 2022
Bristol Myers Squibb is growing rapidly and can serve as a safe haven for investors worried about the current state of the market and economy. The company faces some risks with patent expirations and
A new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?
02:20pm, Thursday, 26'th May 2022
Pfizer Inc.'s PFE, +0.96% promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030 if it's approved by U.S. regulators next year.
Here's how ‘The Big Short' Michael Burry is navigating the financial market now
05:39am, Thursday, 26'th May 2022
Michael Burry, investor, hedge fund manager, and physician known for the “The Big Short” book and movie, seems to be.
Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell?
01:37pm, Wednesday, 25'th May 2022
Both Bristol Myers Squibb and AbbVie spark interest for income- and value-oriented investors. You will see why we favor AbbVie as a better fit for our barbell strategy to build an enduring portfolio f
Pfizer (PFE) Reports More Positive Data From Etrasimod Study
12:41pm, Wednesday, 25'th May 2022 Zacks Investment Research
Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year
We've Only Just Begun
09:17am, Wednesday, 25'th May 2022 Seeking Alpha
Today's stock bear market has only just begun. Elevate your investment strategy to find opportunities that remain abundant within the broader market. Read more.
Michael Burry Says 2022 Is a ‘Plane Crash.' Here's What the Legendary Investor Is Betting On.
03:43pm, Tuesday, 24'th May 2022
Michael Burry is back on Twitter, although his first tweet upon his return is not very supportive of current market conditions. The post Michael Burry Says 2022 Is a ‘Plane Crash.
Why Roche Needs to Invest in At-Home Diagnostics
11:44am, Tuesday, 24'th May 2022 The Motley Fool
Declining demand for COVID-19 screening tests calls for a new focus.
Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use
02:14pm, Monday, 23'rd May 2022 Zacks Investment Research
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
